BACKGROUND: To develop standardized metrics for expected outcomes in lower extremity revascularization for critical limb ischemia (CLI), the Society for Vascular Surgery (SVS) has developed objective performance goals (OPGs) based on aggregate data from randomized trials of lower extremity bypass (LEB). It remains unknown, however, if these targets can be achieved in everyday vascular surgery practice. METHODS: We applied SVS OPG criteria to 1039 patients undergoing 1039 LEB operations for CLI with autogenous vein (excluding patients on dialysis) within the Vascular Study Group of New England (VSGNE). Each of the individual OPGs was calculated within the VSGNE dataset, along with its surrounding 95% confidence intervals (CIs) and compared to published SVS OPGs using χ(2) comparisons and survival analysis. RESULTS: Across most risk strata, patients in the VSGNE and SVS OPG cohorts were similar (clinical high-risk [age >80 years and tissue loss]: 15.3% VSGNE; 16.2% SVS OPG; P = .58; anatomic high risk [infrapopliteal target artery]: 57.8% VSGNE; 60.2% SVS OPG; P = .32). However, the proportion of VSGNE patients designated as conduit high-risk (lack of single-segment great saphenous vein) was lower (10.2% VSGNE; 26.9% SVS OPG;P < .001). The primary safety endpoint, major adverse limb events (MALE) at 30 days, was lower in the VSGNE cohort (3.2%; 95% CI, 2.3-4.6) than the SVS OPG cohort (6.2%; 95% CI, 4.2-8.1; P = .05). The primary efficacy OPG endpoint, freedom from any MALE or postoperative death within the first year (MALE + postoperative death [POD]), was similar between VSGNE and SVS OPG cohorts (77%; 95% CI, 74%-80%) SVS OPG, 74% (95% CI, 71%-77%) VSGNE, P = .58). In the remaining safety and efficacy OPGs, the VSGNE cohort met or exceeded the benchmarks established by the SVS OPG cohort. CONCLUSION: Community and academic centers in everyday vascular surgery practice can meet OPGs derived from centers of excellence in LEB. Quality improvement initiatives, as well as clinical trials, should incorporate OPGs in their outcome measures to facilitate communication and comparison of risk-adjusted outcomes in the treatment of CLI.
BACKGROUND: To develop standardized metrics for expected outcomes in lower extremity revascularization for critical limb ischemia (CLI), the Society for Vascular Surgery (SVS) has developed objective performance goals (OPGs) based on aggregate data from randomized trials of lower extremity bypass (LEB). It remains unknown, however, if these targets can be achieved in everyday vascular surgery practice. METHODS: We applied SVS OPG criteria to 1039 patients undergoing 1039 LEB operations for CLI with autogenous vein (excluding patients on dialysis) within the Vascular Study Group of New England (VSGNE). Each of the individual OPGs was calculated within the VSGNE dataset, along with its surrounding 95% confidence intervals (CIs) and compared to published SVS OPGs using χ(2) comparisons and survival analysis. RESULTS: Across most risk strata, patients in the VSGNE and SVS OPG cohorts were similar (clinical high-risk [age >80 years and tissue loss]: 15.3% VSGNE; 16.2% SVS OPG; P = .58; anatomic high risk [infrapopliteal target artery]: 57.8% VSGNE; 60.2% SVS OPG; P = .32). However, the proportion of VSGNE patients designated as conduit high-risk (lack of single-segment great saphenous vein) was lower (10.2% VSGNE; 26.9% SVS OPG;P < .001). The primary safety endpoint, major adverse limb events (MALE) at 30 days, was lower in the VSGNE cohort (3.2%; 95% CI, 2.3-4.6) than the SVS OPG cohort (6.2%; 95% CI, 4.2-8.1; P = .05). The primary efficacy OPG endpoint, freedom from any MALE or postoperative death within the first year (MALE + postoperative death [POD]), was similar between VSGNE and SVS OPG cohorts (77%; 95% CI, 74%-80%) SVS OPG, 74% (95% CI, 71%-77%) VSGNE, P = .58). In the remaining safety and efficacy OPGs, the VSGNE cohort met or exceeded the benchmarks established by the SVS OPG cohort. CONCLUSION: Community and academic centers in everyday vascular surgery practice can meet OPGs derived from centers of excellence in LEB. Quality improvement initiatives, as well as clinical trials, should incorporate OPGs in their outcome measures to facilitate communication and comparison of risk-adjusted outcomes in the treatment of CLI.
Authors: D J Adam; J D Beard; T Cleveland; J Bell; A W Bradbury; J F Forbes; F G R Fowkes; I Gillepsie; C V Ruckley; G Raab; H Storkey Journal: Lancet Date: 2005-12-03 Impact factor: 79.321
Authors: Michael S Conte; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Lynn Seely; Todd J Lorenz; Hamid Namini; Allen D Hamdan; Sean P Roddy; Michael Belkin; Scott A Berceli; Richard J DeMasi; Russell H Samson; Scott S Berman Journal: J Vasc Surg Date: 2006-04 Impact factor: 4.268
Authors: Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-03-21 Impact factor: 29.690
Authors: Jeanette K Chang; Keith D Calligaro; Sean Ryan; Debra Runyan; Matthew J Dougherty; John J Stern Journal: Ann Vasc Surg Date: 2003-01-15 Impact factor: 1.466
Authors: Philip P Goodney; Lori L Travis; Brahmajee K Nallamothu; Kerianne Holman; Bjoern Suckow; Peter K Henke; F Lee Lucas; David C Goodman; John D Birkmeyer; Elliott S Fisher Journal: Circ Cardiovasc Qual Outcomes Date: 2011-12-06
Authors: Bjoern D Suckow; Philip P Goodney; Brian W Nolan; Ravi K Veeraswamy; Patricia Gallagher; Jack L Cronenwett; Larry W Kraiss Journal: Ann Vasc Surg Date: 2015-02-26 Impact factor: 1.466
Authors: Catherine K Chang; Salvatore T Scali; Robert J Feezor; Adam W Beck; Alyson L Waterman; Thomas S Huber; Scott A Berceli Journal: J Vasc Surg Date: 2014-07-16 Impact factor: 4.268
Authors: Mohammad H Eslami; Gheorghe Doros; Philip P Goodney; Jens Elderup-Jorgenson; Jack L Cronenwett; Marina Malikova; Alik Farber Journal: Ann Vasc Surg Date: 2014-10-12 Impact factor: 1.466
Authors: Jessica P Simons; Andres Schanzer; Brian W Nolan; David H Stone; Jeffrey A Kalish; Jack L Cronenwett; Philip P Goodney Journal: J Vasc Surg Date: 2012-06 Impact factor: 4.268
Authors: J Hunter Mehaffey; Robert B Hawkins; Anna Fashandi; Kenneth J Cherry; John A Kern; Irving L Kron; Gilbert R Upchurch; William P Robinson Journal: J Vasc Surg Date: 2017-06-24 Impact factor: 4.268
Authors: James T McPhee; Philip P Goodney; Andres Schanzer; Shimon Shaykevich; Michael Belkin; Matthew T Menard Journal: J Vasc Surg Date: 2013-02-01 Impact factor: 4.268
Authors: Luke Vierthaler; Peter W Callas; Philip P Goodney; Andres Schanzer; Virenda I Patel; Jack Cronenwett; Daniel J Bertges Journal: J Vasc Surg Date: 2015-07-26 Impact factor: 4.268